Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424353 | 0.77 | CDA (0.45) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL6364684 | 0.76 | LMNA (0.44) | LMNASMN1; SMN2PMP22DNMT1BLM | |
| SCHEMBL40870 | 0.75 | LMNA (0.41) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL20833069 | 0.73 | CDA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6674416 | 0.73 | CDA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL18503533 | 0.72 | LMNA (0.41) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL2177463 | 0.72 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL18503534 | 0.71 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL8600538 | 0.69 | CDA (0.47) | LMNASMN1; SMN2ALDH1A1MTORTHPO | |
| SCHEMBL8600543 | 0.69 | CDA (0.47) | LMNASMN1; SMN2ALDH1A1MTORTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993017035-A1 | 2'ISODIDEOXY-β-D-NUCLEOSIDES AS STABLE ANTIVIRAL AGENTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-09-02 | — | — | WO | claimed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-9938221-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| EP-2299998-B1 | MEDIUM-CHAIN LENGTH FATTY ACIDS AND GLYCERIDES AS NEPHROPROTECTION AGENTS | PROMETIC PHARMA SMT LTD (GB) | 2018-01-03 | — | — | EP | disclosed |
| EP-2632885-B1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LTD (GB) | 2018-01-03 | — | — | EP | disclosed |
| US-9738678-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-08-22 | — | — | US | disclosed |
| US-9682054-B2 | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | PROMETIC PHARMA SMT LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-9532962-B2 | Medium-chain length fatty acids and glycerides as nephroprotection agents | PROMETIC PHARMA SMT LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| WO-2002083120-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | PROMETIC BIOSCIENCES INC. (CA) | 2002-10-24 | — | — | WO | disclosed |
| EP-0969828-B1 | BUTYRATE PRODRUGS DERIVED FROM LACTIC ACID | VERTEX PHARMA (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020115716-A1 | Prodrug, salt or analogue of butyrate sufficient to maintain a serum butyrate concentration of between 10 and 200 mu M for 1 to 8 consecutive hours | CHATURVEDI PRAVIN (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1162884-A4 | ORAL LOW DOSE BUTYRATE COMPOSITIONS | VERTEX PHARMA (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1162884-A1 | ORAL LOW DOSE BUTYRATE COMPOSITIONS | Vertex Pharmaceuticals Incorporated (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6225350-B1 | ADMINISTERING BUTYRATE PRODRUG FOR THERAPY OF CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2000056153-A1 | ORAL LOW DOSE BUTYRATE COMPOSITIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-09-28 | — | — | WO | disclosed |
| EP-0969828-A1 | BUTYRATE PRODRUGS DERIVED FROM LACTIC ACID | Vertex Pharmaceuticals Incorporated (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5880152-A | INFLAMMATORY BOWEL DISEASE | VERTEX PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| WO-1998040064-A1 | BUTYRATE PRODRUGS DERIVED FROM LACTIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TYR, PAH, REN | LMNA 2244/4885SMN1; SMN2 3758/4885ALDH1A1 190/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | LMNA 2244/4885SMN1; SMN2 3758/4885ALDH1A1 190/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | LMNA 2244/4885SMN1; SMN2 3758/4885ALDH1A1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.